Commission of the European Communities (2006) Regulation (EC) No 1901/2006 on medicinal products for paediatric use and amending Regulation (EC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Communities, L378, 1-19.
 European Medicines Agency (2011) Report to the European Commission on companies and products that have benefited from any of the rewards and incentives in the Paediatric Regulation and on the companies that have failed to comply with any of the obligations in this Regulation, covering the year 2010. EMA/163613/2011, 3 May 2011, Human Medicines Development and Evalution.
 European Medicines Agency (2010) Reflection paper on the strategy for paediatric onco-logy early authorization and availability. Review, proposal and stakeholders’ views. Draft. EMA/410778/2010, 3 October 2010, Human Medicines Development and Evalution.
 Gemeinsamer Bundesausschuss (GBA) (2009) Agreement of the Federal Joint Committee on quality assurance measures in the inpatient care of children and adolescents with hemato-oncological diseases according to §137 Part 1 Sentence 3 No. 2 SGB V for hospitals qualified according to § 108 SGB V, dated 16 May 2006, taking effect on 1 Jan 2007, last modified on 18 Dec 2008, taking effect on 1 Jan 2009. http://www.g-ba.de/informationen/richtlinien/47/
 Eichler, H.-G., Abadie, E., Breckenridge, A., Leufkens, H. and Rasi, G. (2012) Open clinical trial data for all? A view from regulators. PLOS Medicine, 9, e1001202. doi:10.1371/journal.pmed.1001202
 Pignatti F. European Medicines Agency (2013) Proactive publication of clinical trial data—Feedback from the EMA workshop. http://www.ema.europa.eu/docs/en_GB/ document_library/ Presentation/2013/05/WC500143654.pdf
 Hoffmann, M. (2009) Definitions and clarifications: An Introduction. In: Boos, J., Merkel, R., Raspe, H. and Schone Seifert, B. Eds., Risks and Benefits in Clinical Trials in Humans: Ethical, Legal and Clinical Studies, Deutscher Arzte-Verlag, Koln, 1-12.
 Raspe, H. and Hüppe, A. (2009) Analysis and considerations of risks and benefits in clinical research. In: Boos, J., Merkel, R., Raspe, H. and Sch?ne-Seifert, B. Eds., Risks and Benefits in Clinical Trials in Humans: Ethical, Legal and Clinical Studies, Deutscher ?rzte-Verlag, K?ln, 13-52.
 Begg, C., Cho, M., Eastwood, S., et al. (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA, 276, 637-639. doi:10.1001/jama.19 96.03540080059030
 Falagas, M.E., Grigori, T. and Ioannidou, E. (2009) A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. Journal of Clinical Epidemiology, 62, 227-231.
 Rothenberger, L.G., Henschel, A.D., Schrey D., Becker, A. and Boos, J. (2011) Metho-dological and ethical aspects of randomized controlled clinical trials in minors with malignant diseases. Pediatric Blood & Cancer, 57, 599-605. doi:10.1002/pbc.23171
 Altman, D.G., Schulz, K.F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gotzsche, P. C. and Lang, T. (CONSORT Group) (Consolidated Standards of Reporting Trials) (2001) The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Annals of Internal Medicine, 134, 663-694. doi:10.7326/0003-4819-134-8-200104170-00012
 Hopewell, S., Dutton, S., Yu, L.M., Chan, A.W. and Altman, D.G. (2010) The quality of reports of randomised trials in 2000 and 2006: Comparative study of articles indexed in PubMed. British Medical Journal, 340, c723.
 Schulz, K.F., Chalmers, I., Grimes, D.A. and Altman, D.G. (1994) Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. The Journal of the American Medical Association, 272, 125-128. doi:10.1001/jama.1994.03520020051014
 Wood, L., Egger, M., Gluud, L.L., Schulz, K.F., Jüni. P., Altman. D.G., Gluud. C., Martin, R.M., Wood, A.J. and Sterne, J.A. (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. British Medical Journal, 336, 601-605. doi:10.1136/bmj.39465.451748.AD
 Noseworthy, J.H., Ebers, G.C., Vandervoort, M.K., Farquhar, R.E., Yetisir, E. and Roberts, R. (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology, 44, 16-20. doi:10.1212/WNL.44.1.16
 International Committee of Medical Journal Editors (ICMJE) (2010) Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. http://www.icmje.org/urm_full.pdf
 NIH (2011) National Institute of Health (NIH)-Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
 Meerpohl, J.J., Wolff, R.F., Antes, G. and von Elm, E. (2011) Are pediatric open access journals promoting good publication practice? An analysis of author instructtions. BioMed Central Pediatrics, 11, 27. http://www.biomedcentral.com/1471-2431/11/27
 Blümle, A., Meerpohl, J.J., Rücker, G., Antes, G., Schumacher, M. and von Elm, E. (2011) Reporting of eligibility criteria of randomised trials: Cohort study comparing trial protocols with subsequent articles. British Medical Journal, 342, d1828.